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Supplementary Figure S1: Cluster randomized trial of PSA testing for Prostate cancer (CAP) trial design  
  
 
 
PSA: Prostate Specific Antigen  
aCluster randomization was blocked and stratified by geographical area as described previously.1 A 9th centre was 
randomized (Edinburgh) but due to regulatory constraints we could not validate cause of death in individual unconsented 
men in the control arm, necessary for the primary analyses. These men were included in the ProtecT consented treatment 
trial as described in ProtecT publications,2-4 but not in the CAP screening trial.1  
  
  
Supplementary Figure S2: Cumulative incidence of prostate cancer in intervention-arm non-attenders for PSA 
screening vs controls (A) and in the post-screening phase (from 18 months post recruitment) amongst men 
who attended for PSA screening in the intervention-arm versus controls (B).  
                               
Number at risk at the start of each year (number of prostate cancer diagnoses in that year) 
Time (year) Median (IQR) 
follow up 
0 1a 2 3 4 5 6 7 8 9 10 11 12 13 14 
A: Control vs. non-attenders, crude rate difference -0.62 per 1000 (95% CI -0.76, -0.48) 
Non-attenders 9.82  
(8.67, 10.92) 
113,679 
(280) 
111,177 
(243) 
108,738 
(233) 
106,429 
(257) 
103,857 
(291) 
101,236 
(299) 
98,709 
(317) 
95,890 
(376) 
92,653 
(334) 
71,396 
(283) 
50,846 
(200) 
32,107 
(151) 
18,633 
(78) 
8,469  
(25) 
827  
(0) 
Control 9.68  
(8.41, 11.27) 
219,439 
(455) 
216,057 
(555) 
212,739 
(597) 
209,018 
(663) 
205,021 
(749) 
200,496 
(758) 
196,022 
(858) 
191,503 
(929) 
185,601 
(881) 
148,182 
(669) 
103,578 
(406) 
48,701 
(206) 
22,905 
(90) 
12,894 
(37) 
1,747  
(0) 
B: Control vs. attenders, crude rate difference -0.56 per 1000 (95% CI -0.70, -0.41) 
Attenders 10.38  
(8.94, 11.88)  
  72,863 
(102) 
72,563 
(138) 
71,956 
(164) 
71,200 
(186) 
70,414 
(200) 
69,525 
(218) 
68,577 
(292) 
67,286 
(259) 
53,750 
(230) 
40,573 
(178) 
27,824 
(115) 
17,589 
(76) 
7,918  
(18) 
762  
(3) 
Control 9.89 
(8.72, 10.93) 
  214,458 
(300) 
212,739 
(597) 
209,018 
(663) 
205,021 
(749) 
200,496 
(758) 
196,022 
(858) 
191,503 
(929) 
185,601 
(881) 
148,182 
(669) 
103,578 
(406) 
48,701 
(206) 
22,905 
(90) 
12,894 
(37) 
1,747 
(0) 
 
The graph in panel B show the cumulative incidence of prostate cancer diagnosis after the removal of the 18 month (1.5 year) ‘screening phase’, CI: 
confidence interval, IQR: interquartile range, a6months follow up only for panel B 
  
  
  
Supplementary Figure S3: Cumulative incidence of prostate cancer by TNM stage at diagnosis. 
                   
Number at risk at the start of each year (number of prostate cancer diagnoses in that year) 
Years 
Median (IQR) 
follow up 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Intervention  189,386 184,549 181,301 178,385 175,057 171,650 168,234 164,467 159,939 125,146 91,419 59,931 36,222 16,387 1,589 
Stage T1/T2 2.96 (0.61, 7.51) (1852) (441) (187) (229) (235) (265) (313) (359) (330) (269) (215) (151) (78) (30) (0) 
Stage T3 5.45 (1.21, 8.57) (303) (97) (56) (76) (85) (97) (81) (135) (105) (117) (85) (50) (37) (5) (1) 
Stage T4/N1/M1a 6.85 (4.08, 9.00) (93) (39) (46) (51) (71) (82) (100) (117) (97) (86) (64) (51) (27) (7) (2) 
Control  219,439 216,057 212,739 209,018 205,021 200,496 196,022 191,503 185,601 148,182 103,578 48,701 22,905 12,894 1,747 
Stage T1/T2 6.18 (3.65, 8.27) (240) (283) (293) (365) (413) (413) (500) (511) (469) (353) (195) (106) (41) (13) (0) 
Stage T3 6.62 (4.00, 8.68) (69) (97) (99) (120) (131) (165) (167) (183) (185) (152) (88) (52) (21) (12) (0) 
Stage T4/N1/M1a 6.77 (4.02, 8.62) (60) (72) (96) (85) (103) (121) (136) (172) (167) (116) (83) (36) (23) (7) (0) 
 
CI: confidence interval; aIf any of these conditions were satisfied patients were categorized as T4, e.g. a patient with T3, N0 and M1 would be T4/N1/M1.  
  
Intevention vs control groups: T1/T2: Difference per 1000 = 6.97, 95% CI (6.05, 7.89); T3: Difference per 1000 = -0.00 (95% CI -0.51, 0.51); T4/N1/M1: Difference per 1000 = -
0.91 (95% CI -1.36, -0.46) 
  
  
Supplementary Figure S4: Cumulative incidence of prostate cancer by Gleason score at diagnosis. 
              
Number at risk at the start of each year (number of prostate cancer diagnoses in that year) 
Years Median (IQR) 
follow up 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
Intervention  189,386  184,549  181,301  178,385  175,057  171,650  168,234  164,467  159,939  125,146 91,419 59,931 36,222 16,387 1,589 
Gleason≤6 1.40 (0.52, 6.42)  (1452)  (311)  (144)  (151)  (167)  (156)  (168)  (197)  (160)  (132) (110) (63) (43) (9) (0) 
Gleason 7 5.07 (0.97, 8.18)  (691)  (235)  (103)  (150)  (172)  (186)  (197)  (255)  (224)  (199) (131) (105) (47) (15) (0) 
Gleason≥8 6.38 (3.03, 8.82)  (184)  (70)  (71)  (81)  (93)  (104)  (123)  (138)  (133)  (108) (91) (59) (35) (10) (3) 
Control  219,439  216,057  212,739  209,018  205,021  200,496  196,022  191,503  185,601  148,182  103,578 48,701 22,905 12,894 1,747 
Gleason≤6 5.69 (3.24, 7.99)  (159)  (202)  (192)  (249)  (259)  (225)  (284)  (264)  (270)  (181) (76) (53) (23) (3) (0) 
Gleason 7 6.28 (3.90, 8.30)  (136)  (176)  (201)  (226)  (277)  (309)  (329)  (360)  (314)  (228) (154) (75) (26) (12) (0) 
Gleason≥8 6.72 (3.91, 8.74)  (86) (103) (109)  (116)  (127)  (158)  (174)  (213)  (194)  (178) (97) (43) (27) (11) (0) 
 
CI: confidence interval; Intevention vs control groups:Gleason≤6: Difference per 1000 = 6.11, 95% CI (5.38, 6.84); Gleason=7: Difference per 1000 = 1.44 (95% CI 0.73, 2.16); 
Gleason≥8: Difference per 1000 = -0.58 (95% CI -1.09, -0.06) 
  
  
  
Supplementary Figure S5: Prostate cancer diagnoses categorized by TNM stagea across the trial groups 
(control group; all men in the intervention group [labelled ‘Intervention’]; men in the intervention group who 
attended for PSA screening [labelled ‘Attended’]; and men in the intervention group who did not attend for 
PSA screening [labelled ‘Not attended’])  
 
 
aA man was given a stage of T4/N1/M1 if he had been diagnosed with stage T4 or was positive for metastases (M1) or nodes (N1). If a man had stage T3 but did not have 
metastates (M0) or nodes (N0) then the diagnosis was categorized as T3. Any diagnoses categorized as T1 or T2 (with no metastasis or nodes) were placed in the T1/T2 
category. 
 
  
  
Supplementary Figure S6: Prostate cancer diagnoses categorized by Gleason scorea across the trial groups 
(control group; all men in the intervention group [labelled ‘Intervention’]; men in the intervention group who 
attended for PSA screening [labelled ‘Attended’]; and men in the intervention group who did not attend for 
PSA screening [labelled ‘Not attended’]) 
 
 
 
aGleason score was calculated as the summation of the primary and secondary Gleason grades.  The score was then broken down into less than or equal to an overall score of 
6, equal to 7, or greater than or equal to 8. 
 
  
  
 
Supplementary Figure S7: Effect of the Cluster randomized trial of PSA testing for Prostate cancer (CAP) trial 
intervention on the cumulative incidence of all-cause mortality 
 
                  
Number at risk at the start of each year (number of deaths in that year)a 
Time (year) Median (IQR) 
follow up 
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
A: Intervention vs. control, crude rate difference 0.23 per 1000 (95% CI -0.00, 0.46) 
Intervention 10.03  
(8.80, 11.50) 
189,386 
(1,772) 
186,989 
(1,888) 
184,370 
(1,900) 
181,778 
(2,212) 
178,777 
(2,215) 
175,750 
(2,302) 
172,702 
(2,479) 
169,353 
(2,581) 
165,313 
(2,500) 
129,718 
(2,028) 
95,089 
(1,629) 
62,558 
(1,085) 
38,003 
(620) 
17,273 
(238) 
1,649 
(10) 
Control 9.92  
(8.74, 10.93) 
219,439 
(1,941) 
216,504 
(2,089) 
213,705 
(2,290) 
210,530 
(2,404) 
207,112 
(2,547) 
203,235 
(2,723) 
199,382 
(2,849) 
195,578 
(3,003) 
190,408 
(2,963) 
152,725 
(2,435) 
107,186 
(1,748) 
50,531 (747) 23,811 
(471) 
13,468 
(187) 
1,816 
(9) 
  
Supplementary Table S1: Data flow amongst participants in the Cluster randomized trial of PSA testing for Prostate cancer (CAP) trial intervention-arm1 compared 
with the previously published ProtecT trial2-4 
 ProtecT   CAP intervention-groupa 
 
Total N  Total N Prostate cancer diagnoses Prostate cancer deathsb 
PSA test non-attenders 128,522  113,679 3,367 361 
PSA test attenders 100,444  75,707 4,687 188 
      No PSA taken/no valid test     18,014       11,271       527        42 
      Valid test     82,430       64,436       4,160        146 
            PSA<3ng/ml           73,538            57,326             1,172              68 
            PSA ≥20ng/ml           280            218             196              19 
            No result           46            35             4              0 
            3≤PSA<20ng/ml (eligible for biopsy within ProtecT)           8,566            6,857             2,788              59 
                  No biopsy                1,152                 1,007                   174                    15 
                  Biopsy                7,414                 5,850                   2,614                    44 
                      Negative biopsy result                     4,518                       3,546                         365                          4 
                      Positive biopsy result                     2,896                       2,304                         2,249c                          40 
                             Randomised-group                             1,643                              1,216                                1,184                                 8 
                             Preference-groupd                             997                              733                                721                                 9 
                            Advanced cancer                             267                              164                                164                                 18 
Excluded, localised cancer                             290                              190                                179                                 5 
Two-arm randomizatione                             24                              1                                1                                 0 
The flow of participants in the intervention arm is detailed: column 2 (ProtecT) shows the Ns reported in the previously published ProtecT trial; column 3 shows the N for those who are included in the 
intervention arm in CAP; columns 4 and 5 show the prostate cancer diagnoses and prostate cancer deaths in men as they flow through the stages of the trial.  PSA: Prostate specific antigen.  
aExcludes the ProtecT Edinburgh centre, feasibility practices and early ProtecT phase practices not randomised into CAP. bDefinite, probable or intervention related prostate cancer death 
cThere were 55 patients that were not flagged by routine data sources as having been diagnosed. Inclusion of these in a sensitivity analysis did not alter any results. 
  
dEligible for randomization into the ProtecT trial but declined to be randomly assigned and expressed a preference for a particular treatment  
eEligible for randomization into the ProtecT trial but agreed to be randomized to two of the three treatment groups only; radiotherapy and radical prostatectomy  
  
Supplementary Table S2: Sensitivity analysis based on comparing alternative definitions of prostate cancer mortality in intervention vs. control groups at 10-year 
median follow-up    
 
 Intervention group 
(n=189,386) 
Person years=1,853,167 
Control group 
(n=219,439) 
Person years=2,095,405 
     Instrumental variable 
estimatea 
 
 
Deaths (%) 
Rate per 1000 
person-years 
(95% CI) 
 
Deaths (%) 
Rate per 1000 
person-years 
(95% CI) 
 
Rate difference 
per 1000 men 
(95% CI) 
 
 
Rate ratio 
(95% CI)b 
P valueb 
Rate ratio  
(95% CI) 
P value 
Defined as definite, 
probable or possible 
prostate cancer death or 
IRDc 
560 
(0.30%) 
0.30  
(0.28, 0.33) 
655 
(0.30%) 
0.32  
(0.29, 0.34) 
 
-0.015  
(-0.050, 0.020) 
 
0.95  
(0.84, 1.08) 
0.42 
0.91  
(0.65, 1.27) 
0.58 
Defined as definite only 
prostate cancer death or 
IRDc 
436 
(0.23%) 
0.24 
(0.21, 0.26) 
510 
(0.23%) 
0.24 
(0.22, 0.27) 
 
-0.008  
(-0.039, 0.022) 
 
0.97  
(0.85, 1.12) 
0.69 
0.93  
(0.66, 1.32) 
0.69 
Defined as definite or 
probable prostate cancer 
deaths or IRD, and also 
including deaths in the 
presence of castrate 
resistant prostate 
cancerc 
593 
(0.31%) 
0.32  
(0.30, 0.35) 
699 
(0.32%) 
0.33 
(0.31, 0.36) 
 
-0.014 
(-0.049, 0.022) 
 
0.96  
(0.86, 1.08) 
0.497 
0.93 
(0.68, 1.27) 
0.64 
CI: confidence interval; IRD: intervention related death 
aAnalysis to obtain the causal effect of screening amongst those attending the prostate specific antigen (PSA) testing clinic using a generalized method of moments 
(gmm) estimator with random allocation as an instrumental variable. 
bLikelihood ratio test of the null hypothesis “no difference in prostate cancer mortality between the groups”, adjusted for randomisation cluster and age stratum. 
cAs determined by the independent cause of death committee 
  
 
  
Supplementary Table S3: Underlying causes of deatha in intervention versus control groups at 10-year median follow-up (not including prostate cancer)  
 
Cause of death Intervention n (%) Control n (%) 
Any (not incl. prostate cancer) 24,910 (100%) 27,659 (100%) 
Other cancers 9,984 (40%) 11,066 (40%) 
Ischemic heart disease 1,141 (5%) 1,287 (5%) 
Stroke 4,763 (19%) 5,217 (19%) 
Other circulatory diseases 1,648 (7%) 1,767 (6%) 
Respiratory disease 2,754 (11%) 3,100 (11%) 
Digestive disease 1,437 (6%) 1,576 (6%) 
Infectious disease 233 (1%) 237 (1%) 
Blood, immune, endocrine 497 (2%) 561 (2%) 
Nervous system disease 807 (3%) 960 (3%) 
Accident 660 (3%) 777 (3%) 
Other 986 (4%) 1,111 (4%) 
aCauses of death were determined by death certificate 
 
 
 
  
Supplementary Table S4: Effect of the Cluster randomized trial of PSA testing for Prostate cancer (CAP) intervention on characteristics of prostate cancer 
cases at diagnosis, by time-period (≤18 vs. >18 months) 
  Intervention group (n=189,386) Controls (n=219,439) 
 
 
Number of prostate cancers (%): 
 
 
 
Attended PSA clinic 
(n=75,707) 
4687 (6.2%) 
Did not attend PSA 
clinic (n=113,679) 
3367 (3.0%) 
All invited 
 
8054 (4.3%) 
7853 (3.6%) 
Clinical characteristics at diagnosis for those diagnosed within 18 months of 
randomization 
   
Number of prostate cancers/number at risk (%)  2,508/75,707 (3.31%) 404/113,679 (0.36%) 2,912/189,386 (1.54%) 710/219,439 (0.32%) 
Person years of follow up   111,375 168,013 279,388 326,081 
Rate per 1000 person-years (95% CI)  22.52 (21.65, 23.42) 2.40 (2.18, 2.65) 10.42 (10.05, 10.81) 2.18 (2.02, 2.34) 
Grade (%) ≤6 1,497 (1.98%) 166 (0.15%) 1,663 (0.86%) 250 (0.11%) 
 7 732 (0.97%) 124 (0.11%) 856 (0.45%) 215 (0.10%) 
 ≥8 169 (0.22%) 56 (0.05%) 225 (0.12%) 131 (0.06%) 
 No record 110 (0.15%) 58 (0.05%) 198 (0.10%) 114 (0.05%) 
Stage (%) T1/T2 1,949 (2.57%) 205 (0.18%) 2,154 (1.14%) 364 (0.17%) 
 T3 310 (0.41%) 60 (0.05%) 370 (0.20%) 107 (0.05%) 
 T4/N1/M1  59 (0.08%) 58 (0.05%) 117 (0.06%) 96 (0.04%) 
 No record 190 (0.25%) 81 (0.07%) 271 (0.14%) 143 (0.07%) 
Clinical characteristics at diagnosis for those diagnosed over 18 months after randomization   
Number of prostate cancers/number at risk (%)  2179/72,863 (2.99%) 2963/110,017 (2.69%) 5142/182,880 (2.81%) 7143/214,458 (3.33%) 
Person years of follow up   639,198 889,445 1,528,643 1,737,831 
Rate per 1000 person-years (95% CI)  3.41 (3.27, 3.56) 3.33 (3.21, 3.45) 3.36 (3.27, 3.46) 4.11 (4.02, 4.21) 
Grade (%) ≤6 800 (1.06%) 800 (0.70%) 1,600 (0.84%) 2,190 (1.00%) 
 7 794 (1.05%) 1,060 (0.93%) 1,854 (0.98%) 2,608 (1.19%) 
 ≥8 396 (0.52%) 682 (0.60%) 1,078 (0.57%) 1,505 (0.69%) 
  
  Intervention group (n=189,386) Controls (n=219,439) 
 
 
Number of prostate cancers (%): 
 
 
 
Attended PSA clinic 
(n=75,707) 
4687 (6.2%) 
Did not attend PSA 
clinic (n=113,679) 
3367 (3.0%) 
All invited 
 
8054 (4.3%) 
7853 (3.6%) 
 No record 189 (0.25%) 421 (0.37%) 610 (0.32%) 840 (0.38%) 
Stage (%) T1/T2 1,359 (1.80%) 1,425 (1.25%) 2,784 (1.47%) 3,828 (1.74%) 
 T3 380 (0.50%) 579 (0.51%) 959 (0.51%) 1,433 (0.65%) 
 T4/N1/M1  242 (0.32%) 571 (0.50%) 813 (0.43%) 1,181 (0.54%) 
 No record 198 (0.26%) 388 (0.34%) 586 (3.09%) 701 (0.32%) 
  
Supplementary Table S5: Summary description of intervention related deaths as determined by 
the Independent Cause of Death Committee5 
 
Post-operative 
(n=5) 
Post 
chemotherapy 
(n=2) 
Post 
radiation 
(n=2) 
Post hormones (n=3) Post investigative 
procedures, e.g. biopsy 
(n=3) 
Sudden death 5 
days after 
Radical 
Prostatectomy  
Sepsis Proctitis Cardiovascular event Transurethral resection 
of bladder tumor 
(TURBT), transurethral 
resection of the 
prostate (TURP) & 
pelvic mass biopsy 
conducted a few days 
prior to death 
Perforated 
diverticular 
disease  
Neutropenic 
sepsis 
Hemorrhagic 
cystitis 
Cardiac event Post biopsy 
complications 
Bleeding   Pulmonary embolism Deterioration of existing 
kidney disease linked to 
CT scan 
Renal failure     
Sepsis     
Orange shading = deaths in the intervention-group; blue shading = deaths in the control-group.  
 
  
  
Supplementary Table S6: Characteristics of CAP1, ERSPC6 and PLCO7 randomized trials of prostate 
cancer screening 
 
 CAP ERSPC PLCO 
Performance Characteristics   
Number in 
intervention arm 
189,386 72,952 38,343 
Number in control 
arm 
219,439 89,353 38,350 
Mean age at baseline a 
(years) 
59.0 61.5 NA 
Number PSA-tested in 
intervention-group 
67,312 59,923 ≈32,600 
Proportion PSA-tested 
in intervention-group  
36% 64%b 85% 
Recommend PSA 
threshold for biopsy 
referral 
3ng/ml 3-4ng/ml (variable 
across countries) 
4ng/ml 
Rates of biopsy in men 
with raised PSA 
85% 86% 41%8 
PSA contamination 
amongst controls 
(screening in the 
control arm) 
≈10-15% 
asymptomatic PSA 
tests with screening 
intent9 
ERSPC Rotterdam 
≈15% asymptomatic 
PSA tests after 
randomization10 
PLCO≈50% per year7 
Prostate cancer 
detection in the 
control group 
7853/219439 
3.6% over 10 years 
4307/89353 
4.8% over 9 years 
2974/38350 
7.8% over 7-10 years 
Prostate cancer 
detection in the 
intervention group 
8054/189386 
4.3% over a median of 
10 years 
5990/72,952 
8.2% over a median of 
9 years6 
3452/38343 
9.0% over 7-10 years7 
Characteristics of diagnosed prostate cancers in controlsc  
Gleason grade ≤6 35% 55% 62% 
Gleason grade 7 41% 29% 27% 
Gleason grade ≥8 24% 16% 12% 
Stage T1/2 60% 79% 95% 
Characteristics of diagnosed prostate cancers in the intervention groupc 
Gleason grade ≤6 45% 72% 67% 
Gleason grade 7 37% 20% 24% 
Gleason grade ≥8 18% 7% 9% 
Stage T1/2 69% 90% 97% 
Mean age at prostate 
cancer diagnosis (yrs) 
67 61 NK 
CAP: Cluster randomized trial of PSA testing for Prostate cancer, ERSPC: European Randomised Study of 
Screening for Prostate Cancer, PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, NA: not 
available, PSA: Prostate specific antigen, aCAP mean age at invitation; ERSPC mean age at randomization. bIn 
ERSPC centers where randomization was based on men identified from population registries and consented 
post-randomization (as in CAP), the participation rate in the screening arm varied from 59% to 69% (mean: 
64%) (compliance was considerably higher in centers with pre-randomization consent).11  cFigures for ERSPC 
and PLCO were derived from those reported in order to remove ‘missing/not yet reported’ from the 
denominator.   
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